Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in…
The Archive
Every market briefing, in one place.
In-depth analysis on the Fed, earnings, labor, commodities, and the news that moves markets. Filter by topic to find what you’re looking for.
Goldman Sachs turns bearish on Barbie maker
Wall Street has spent most of 2026 losing patience with Mattel (MAT), and Goldman Sachs just made that clear. The…
What This Immunome Sale Means a Day Before a Big FDA Milestone
Key Points An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026…
Retiring with $1.2 Million? Here’s How to Avoid Running Out of Savings
Key Points As always, The Motley Fool cannot and does not provide personalized investing or financial advice. This information is…
1 Low-Cost Vanguard ETF Could Turn $300 per Month Into a $1 Million Portfolio. Here’s How.
Key Points Even modest monthly investments can grow into substantial sums, given the right strategy and enough time. For long-term…
Amazon Just Announced Shocking $25 Billion News. Should Investors Worry?
Key Points Amazon (NASDAQ: AMZN) is reported to have made a shocking decision in recent days. According to CNBC, it…
Prediction: SpaceX Shares Can Reach $220 by End of 2026
Key Points SpaceX’s post-IPO pullback has shifted investor focus toward the company’s next phase of growth. Starlink, AI compute contracts,…
J.P. Morgan Called a Potential Elon Musk SpaceX-Tesla Merger “Strategically Coherent”
Key Points Now that Elon Musk’s rocket and satellite company Space Exploration Technologies (NASDAQ: SPCX) trades publicly, Wall Street has…
Kymera’s CEO Sold $6 Million in Stock After a 170% Run
Key Points According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale…